HSHHSH Health Technology Supplier Hub
Home › Suppliers › Johnson & Johnson MedTech › Risk

Johnson & Johnson MedTech: risk summary

Summaries are drawn from public sources and link to them. HSH does not give a risk rating: read the summary and sources and reach your own view. Unproven allegations are labelled as such. Suppliers can submit a response, which is shown alongside.

Financial

Latest full-year results from official filings.

Parent Johnson & Johnson (JNJ) group FY2025 revenue $94.19bn (+6.0%); pre-tax margin 34.6%; net income $26.80bn.

MedTech segment sales $33.79bn (+6.1%).

Researched 8 Nov 2026

Adverse media

Credible news about incidents, disputes, legal action or restructuring in the last 24 months.

Not yet researched.

Cyber & information governance

Data breaches, cyber incidents, regulator action and assurance status.

Not yet researched.

Regulatory & clinical safety

Recalls, safety notices, regulator action and clinical safety concerns.

Not yet researched.

Contract performance

Contract delivery, go-lives, terminations and disputes.

Not yet researched.